Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
AVXL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.25 - $14.44
Previous CloseN/A
Volume1.46M
Average Volume (3M)1.40M
Market Cap
$740.06M
Enterprise Value$349.45M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.92
Next Earnings
May 08, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding85,064,200
10 Day Avg. Volume967,307
30 Day Avg. Volume1,395,302
Standard Deviation0.25
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-15.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.80
Forecast
1Y Price Target
$42.00Price Target Upside383.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Anavex Life Sciences News
PremiumCompany Announcements
Anavex Life Sciences Earnings Call Highlights Progress and Challenges
PremiumCompany Announcements
Anavex Life Sciences Reports Higher Quarterly Loss Amid R&D Focus---
Bulls Say, Bears Say
Bulls Say
Financial ResourcesThe company finished the period ending December 31, 2024, with $120.8M in cash and cash equivalents, which it expects to be sufficient to fund operations at the current cash utilization rate for roughly four years.
Market OpportunityThe European market opportunity for blarcamesine could be highly lucrative, with an estimated 7 million people in Europe with Alzheimer's disease.
Bears Say
Regulatory RisksRisks include negative clinical data with blarcamesine in Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome, and possible long-term dilution risk.
---
Ownership Overview
3.04% Insiders
8.55% Mutual Funds
4.37% Other Institutional Investors
71.77% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVXL FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest stock price was $3.25 and its highest was $14.44 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Anavex Life Sciences’s market cap is $740.06M.
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is May 08, 2025 which is in 75 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Feb 12, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.03.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate is -0.15.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 85,064,200 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went up 4.946%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Currently, no hedge funds are holding shares in AVXL
---
Anavex Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.00 (383.87% Upside)
$42.00 (383.87% Upside)
Blogger Sentiment
Bullish
AVXL Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 15.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.94%
12-Months-Change
Fundamentals
Return on Equity
-37.72%
Trailing 12-Months
Asset Growth
-16.23%
Trailing 12-Months
Company Description
Anavex Life Sciences
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
---
AVXL Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The conference call highlighted significant progress in Alzheimer’s treatment development, including promising trial results and a new patent. Financial stability and strategic clinical trials were also emphasized. However, increased expenses, net losses, and delays in certain programs were noted as challenges. Overall, the sentiment is cautiously optimistic, reflecting both achievements and areas needing further clarity.Read More>---
AVXL Stock 12 Month Forecast
Average Price Target
$42.00
▲(383.87% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Biogen
―
Cassava Sciences
―
Axsome Therapeutics
―
Adial Pharmaceuticals
―
Best Analysts Covering AVXL
1 Year
1 Year Success Rate
16/27 ratings generated profit
1 Year Average Return
+89.36%
initiated a buy rating 7 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 59.26% of your transactions generating a profit, with an average return of +89.36% per trade.
---